Corrigendum to “Photothermic Therapy With Cuttlefish Ink-Based Nanoparticles in Combination With Anti-Ox40 Mab Achieve Remission of Triple-Negative Breast Cancer” [Int. Immunopharmacol. 115 (2023) 109622] (International Immunopharmacology (2023) 115, (S1567576922011079), (10.1016/J.Intimp.2022.109622))

Corrigendum to “Photothermic Therapy With Cuttlefish Ink-Based Nanoparticles in Combination With Anti-Ox40 Mab Achieve Remission of Triple-Negative Breast Cancer” [Int. Immunopharmacol. 115 (2023) 109622] (International Immunopharmacology (2023) 115, (S1567576922011079), (10.1016/J.Intimp.2022.109622)) Publisher Pubmed

Momenzadeh N¹ ; Hajian S¹ ; Shabankare A² ; Ghavimi R^{3, 4} ; Kabirisamani S⁵ ; Kabiri H⁵ ; Hesamizadeh K⁶ ; Shabankareh ANT⁷ ; Nazaraghay R¹ ; Nabipour I¹ ; Mohammadi M^{1, 8}

Source: International Immunopharmacology Published:2023

Abstract

In Figure 7, H&D staining for mouse from group 1 (G1) is similar to mouse from group 3 (G3), but not identical. The authors apologize for any inconvenience this has caused. The extremely poor figure quality generated the above comment. We sought a correction to the figure for further clarity. Since the original version of paper was published, the following change has been made to the publication. Figure 7 [Figure Presented].a's section G3 has been replaced by a new figure. © 2023

Related Docs

View other Related Docs

1. Corrigendum to “Thermosensitive Chitosan/Poly(N-Isopropyl Acrylamide) Nanoparticles Embedded in Aniline Pentamer/Silk Fibroin/Polyacrylamide As an Electroactive Injectable Hydrogel for Healing Critical-Sized Calvarial Bone Defect in Aging Rat Model” [Int. J. Biol. Macromol.; Volume 213, 31 July 2022, Pages 352-368] (International Journal of Biological Macromolecules (2022) 213 (352–368), (S0141813022011667), (10.1016/J.Ijbiomac.2022.05.176)), International Journal of Biological Macromolecules (2025)

2. Corrigendum to “Alginate/Gum Arabic-Based Biomimetic Hydrogel Enriched With Immobilized Nerve Growth Factor and Carnosine Improves Diabetic Wound Regeneration” [Carbohydrate Polymers 321, (2023), 121179](S0144861723006446)(10.1016/J.Carbpol.2023.121179), Carbohydrate Polymers (2025)

3. Retracted Article: Rapamycin Augments Immunomodulatory Properties of Bone Marrow-Derived Mesenchymal Stem Cells in Experimental Autoimmune Encephalomyelitis (Molecular Neurobiology, (2017), 54, 4, (2445-2457), 10.1007/S12035-016-9840-3), Molecular Neurobiology (2024)

Experts (# of related papers)

View all Related Experts

Fatemeh Atyabi (3)

Rassoul Dinarvand (3)

Style	Citing Format
MLA	Momenzadeh N, et al.. "Corrigendum to “Photothermic Therapy With Cuttlefish Ink-Based Nanoparticles in Combination With Anti-Ox40 Mab Achieve Remission of Triple-Negative Breast Cancer” [Int. Immunopharmacol. 115 (2023) 109622] (International Immunopharmacology (2023) 115, (S1567576922011079), (10.1016/J.Intimp.2022.109622))." International Immunopharmacology, vol. 124, no. , 2023, pp. -.
APA	Momenzadeh N, Hajian S, Shabankare A, Ghavimi R, Kabirisamani S, Kabiri H, Hesamizadeh K, Shabankareh ANT, Nazaraghay R, Nabipour I, Mohammadi M (2023). Corrigendum to “Photothermic Therapy With Cuttlefish Ink-Based Nanoparticles in Combination With Anti-Ox40 Mab Achieve Remission of Triple-Negative Breast Cancer” [Int. Immunopharmacol. 115 (2023) 109622] (International Immunopharmacology (2023) 115, (S1567576922011079), (10.1016/J.Intimp.2022.109622)). International Immunopharmacology, 124(), -.
Chicago	Momenzadeh N, Hajian S, Shabankare A, Ghavimi R, Kabirisamani S, Kabiri H, Hesamizadeh K, et al.. "Corrigendum to “Photothermic Therapy With Cuttlefish Ink-Based Nanoparticles in Combination With Anti-Ox40 Mab Achieve Remission of Triple-Negative Breast Cancer” [Int. Immunopharmacol. 115 (2023) 109622] (International Immunopharmacology (2023) 115, (S1567576922011079), (10.1016/J.Intimp.2022.109622))." International Immunopharmacology 124, no. (2023): -.
Harvard	Momenzadeh N et al. (2023) 'Corrigendum to “Photothermic Therapy With Cuttlefish Ink-Based Nanoparticles in Combination With Anti-Ox40 Mab Achieve Remission of Triple-Negative Breast Cancer” [Int. Immunopharmacol. 115 (2023) 109622] (International Immunopharmacology (2023) 115, (S1567576922011079), (10.1016/J.Intimp.2022.109622))', International Immunopharmacology, 124(), pp. -.
Vancouver	Momenzadeh N, Hajian S, Shabankare A, Ghavimi R, Kabirisamani S, Kabiri H, et al.. Corrigendum to “Photothermic Therapy With Cuttlefish Ink-Based Nanoparticles in Combination With Anti-Ox40 Mab Achieve Remission of Triple-Negative Breast Cancer” [Int. Immunopharmacol. 115 (2023) 109622] (International Immunopharmacology (2023) 115, (S1567576922011079), (10.1016/J.Intimp.2022.109622)). International Immunopharmacology. 2023;124():-.
BibTex	@article{ author = {Momenzadeh N and Hajian S and Shabankare A and Ghavimi R and Kabirisamani S and Kabiri H and Hesamizadeh K and Shabankareh ANT and Nazaraghay R and Nabipour I and Mohammadi M}, title = {Corrigendum to “Photothermic Therapy With Cuttlefish Ink-Based Nanoparticles in Combination With Anti-Ox40 Mab Achieve Remission of Triple-Negative Breast Cancer” [Int. Immunopharmacol. 115 (2023) 109622] (International Immunopharmacology (2023) 115, (S1567576922011079), (10.1016/J.Intimp.2022.109622))}, journal = {International Immunopharmacology}, volume = {124}, number = {}, pages = {-}, year = {2023} }
RIS	TY - JOUR AU - Momenzadeh N AU - Hajian S AU - Shabankare A AU - Ghavimi R AU - Kabirisamani S AU - Kabiri H AU - Hesamizadeh K AU - Shabankareh ANT AU - Nazaraghay R AU - Nabipour I AU - Mohammadi M TI - Corrigendum to “Photothermic Therapy With Cuttlefish Ink-Based Nanoparticles in Combination With Anti-Ox40 Mab Achieve Remission of Triple-Negative Breast Cancer” [Int. Immunopharmacol. 115 (2023) 109622] (International Immunopharmacology (2023) 115, (S1567576922011079), (10.1016/J.Intimp.2022.109622)) JO - International Immunopharmacology VL - 124 IS - SP - EP - PY - 2023 ER -

Style

Citing Format

MLA

Momenzadeh N, et al.. "Corrigendum to “Photothermic Therapy With Cuttlefish Ink-Based Nanoparticles in Combination With Anti-Ox40 Mab Achieve Remission of Triple-Negative Breast Cancer” [Int. Immunopharmacol. 115 (2023) 109622] (International Immunopharmacology (2023) 115, (S1567576922011079), (10.1016/J.Intimp.2022.109622))." International Immunopharmacology, vol. 124, no. , 2023, pp. -.

APA

Momenzadeh N, Hajian S, Shabankare A, Ghavimi R, Kabirisamani S, Kabiri H, Hesamizadeh K, Shabankareh ANT, Nazaraghay R, Nabipour I, Mohammadi M (2023). Corrigendum to “Photothermic Therapy With Cuttlefish Ink-Based Nanoparticles in Combination With Anti-Ox40 Mab Achieve Remission of Triple-Negative Breast Cancer” [Int. Immunopharmacol. 115 (2023) 109622] (International Immunopharmacology (2023) 115, (S1567576922011079), (10.1016/J.Intimp.2022.109622)). International Immunopharmacology, 124(), -.

Chicago

Momenzadeh N, Hajian S, Shabankare A, Ghavimi R, Kabirisamani S, Kabiri H, Hesamizadeh K, et al.. "Corrigendum to “Photothermic Therapy With Cuttlefish Ink-Based Nanoparticles in Combination With Anti-Ox40 Mab Achieve Remission of Triple-Negative Breast Cancer” [Int. Immunopharmacol. 115 (2023) 109622] (International Immunopharmacology (2023) 115, (S1567576922011079), (10.1016/J.Intimp.2022.109622))." International Immunopharmacology 124, no. (2023): -.

Harvard

Momenzadeh N et al. (2023) 'Corrigendum to “Photothermic Therapy With Cuttlefish Ink-Based Nanoparticles in Combination With Anti-Ox40 Mab Achieve Remission of Triple-Negative Breast Cancer” [Int. Immunopharmacol. 115 (2023) 109622] (International Immunopharmacology (2023) 115, (S1567576922011079), (10.1016/J.Intimp.2022.109622))', International Immunopharmacology, 124(), pp. -.

Vancouver

Momenzadeh N, Hajian S, Shabankare A, Ghavimi R, Kabirisamani S, Kabiri H, et al.. Corrigendum to “Photothermic Therapy With Cuttlefish Ink-Based Nanoparticles in Combination With Anti-Ox40 Mab Achieve Remission of Triple-Negative Breast Cancer” [Int. Immunopharmacol. 115 (2023) 109622] (International Immunopharmacology (2023) 115, (S1567576922011079), (10.1016/J.Intimp.2022.109622)). International Immunopharmacology. 2023;124():-.

BibTex

@article{ author = {Momenzadeh N and Hajian S and Shabankare A and Ghavimi R and Kabirisamani S and Kabiri H and Hesamizadeh K and Shabankareh ANT and Nazaraghay R and Nabipour I and Mohammadi M}, title = {Corrigendum to “Photothermic Therapy With Cuttlefish Ink-Based Nanoparticles in Combination With Anti-Ox40 Mab Achieve Remission of Triple-Negative Breast Cancer” [Int. Immunopharmacol. 115 (2023) 109622] (International Immunopharmacology (2023) 115, (S1567576922011079), (10.1016/J.Intimp.2022.109622))}, journal = {International Immunopharmacology}, volume = {124}, number = {}, pages = {-}, year = {2023} }

RIS

TY - JOUR
AU - Momenzadeh N
AU - Hajian S
AU - Shabankare A
AU - Ghavimi R
AU - Kabirisamani S
AU - Kabiri H
AU - Hesamizadeh K
AU - Shabankareh ANT
AU - Nazaraghay R
AU - Nabipour I
AU - Mohammadi M
TI - Corrigendum to “Photothermic Therapy With Cuttlefish Ink-Based Nanoparticles in Combination With Anti-Ox40 Mab Achieve Remission of Triple-Negative Breast Cancer” [Int. Immunopharmacol. 115 (2023) 109622] (International Immunopharmacology (2023) 115, (S1567576922011079), (10.1016/J.Intimp.2022.109622))
JO - International Immunopharmacology
VL - 124
IS -
SP -
EP -
PY - 2023
ER -

Science Communicator Platform

Authors

Abstract